BlackRock Discloses 5.0% Passive Stake in Vera Therapeutics
Ticker: VERA · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, pharmaceuticals
TL;DR
**BlackRock just revealed a 5% passive stake in Vera Therapeutics.**
AI Summary
BlackRock, Inc. reported on January 29, 2024, that as of December 31, 2023, it beneficially owns 2,008,637 shares of Vera Therapeutics, Inc. Class A Common Stock, representing 5.0% of the company. This filing indicates BlackRock's significant, but passive, stake in the pharmaceutical company. For investors, this means a major institutional investor sees value in Vera Therapeutics, potentially signaling confidence in its future, but BlackRock isn't looking to actively influence management.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant stake in Vera Therapeutics, which can be seen as a vote of confidence in the company's prospects.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally doesn't pose a direct risk to current shareholders.
Analyst Insight
A smart investor would note BlackRock's passive 5.0% stake as a potential sign of institutional confidence in Vera Therapeutics, but understand it doesn't imply active management involvement or an impending takeover. Further research into Vera Therapeutics' fundamentals and pipeline would be prudent.
Key Numbers
- 2,008,637 — Shares Beneficially Owned (Represents the total number of Class A Common Stock shares of Vera Therapeutics, Inc. held by BlackRock, Inc. as of December 31, 2023.)
- 5.0% — Ownership Percentage (Indicates BlackRock, Inc.'s percentage of ownership of Vera Therapeutics, Inc.'s Class A Common Stock, making it a significant shareholder.)
Key Players & Entities
- BlackRock, Inc. (company) — reporting person, institutional investor
- Vera Therapeutics, Inc. (company) — subject company, issuer of securities
- 2,008,637 (dollar_amount) — number of shares beneficially owned by BlackRock
- 5.0% (dollar_amount) — percentage of Class A Common Stock owned by BlackRock
- December 31, 2023 (person) — date of event requiring the filing
Forward-Looking Statements
- BlackRock will maintain its passive stake in Vera Therapeutics for the foreseeable future. (BlackRock, Inc.) — high confidence, target: 2025-12-31
- Vera Therapeutics' stock price may see a slight positive sentiment bump due to BlackRock's disclosed stake. (Vera Therapeutics, Inc.) — medium confidence, target: 2024-03-31
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock, Inc., as stated in the 'Names of reporting persons' section of the filing.
What is the subject company whose securities are being reported on?
The subject company is Vera Therapeutics, Inc., as identified under 'Name of Issuer' in the filing.
What type of securities did BlackRock, Inc. report owning?
BlackRock, Inc. reported owning Class A Common Stock of Vera Therapeutics, Inc., as specified under 'Title of Class of Securities'.
As of what date did the event requiring this filing occur?
The event requiring this filing occurred on December 31, 2023, as indicated by 'Date of Event Which Requires Filing of this Statement'.
What percentage of Vera Therapeutics, Inc.'s Class A Common Stock does BlackRock, Inc. beneficially own?
BlackRock, Inc. beneficially owns 5.0% of Vera Therapeutics, Inc.'s Class A Common Stock, based on the filing's details.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding Vera Therapeutics, Inc. (VERA).